Juliet Williams
Woomera Therapeutics(US)C4 Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Hedgehog Signaling Pathway Studies, Melanoma and MAPK Pathways, Computational Drug Discovery Methods, CAR-T cell therapy research
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- → Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma(2010)553 cited
- → The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival(2017)350 cited
- → Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist(2010)325 cited
- → Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions(2003)298 cited
- → SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors(2018)200 cited
- → Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling(2020)159 cited
- → KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer(2017)155 cited
- → 1-Amino-4-benzylphthalazines as Orally Bioavailable Smoothened Antagonists with Antitumor Activity(2009)106 cited
- → Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field(2018)94 cited